GS-5423
Sponsors
Gilead Sciences Inc., National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford
Conditions
HIVHIV-1HIV-1-infection
Phase 1
Phase 2
Phase 3
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing
Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens
Not yet recruitingCTIS2025-524336-19-00
Target: 10Updated: 2026-07-21
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
Not yet recruitingCTIS2025-524335-39-00
Target: 37Updated: 2026-07-22